AAC just published a review from the WHO advisory panel on the antibacterial pipeline analyzing ‘traditional’ and ‘non-traditional’ antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens, mycobacteria and Clostridioides difficile. Today, we will dissect this important publication
• Understand the role of the WHO in antimicrobial resistance
• Discuss the analysis of the antibacterial pipeline
• Deliberate on important highlights from the review and the future of antibacterial research.
- Dr. Peter Beyer, Senior Advisor for the Antimicrobial Resistance Division at the World Health Organization.
- Dr. Mark Butler, MSBChem Consulting, Brisbane, Queensland, Australia
- Dr. Prabhavathi Fernandes. Member, Scientific Advisory Committee, GARDP, Geneva, Switzerlandand The National Biodefense Science 17Board, Health and Human Services, Washington DC, USA
This episode of Editors in Conversation is brought to you by the Antimicrobial Agents and Chemotherapy Journal and hosted by AAC Editor in Chief, Cesar Arias. AAC is available at https://aac.asm.org. Follow Cesar on twitter at https://twitter.com/SuperBugDoc for AAC updates.
Subscribe to the podcast at https://asm.org/eic
The applications of large multiplex panels for detection of pathogens have greatly expanded in the past several years. Initial tests were for detection of respiratory viruses, and the first such test was labor intensive and vulnerable to frequent contamination. Since then, additional sample types...
COVID-19 continues to pose major problems in the winter in the USA. Infections and hospitalizations are increasing and there is a fear of emergence of new variants. Therapeutic tools are also evolving. We discuss these new developments!
Watch the video version via: https://youtu.be/ElnahBl53e8